NCT00498667
Withdrawn
Not Applicable
Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
- Sponsor
- Rambam Health Care Campus
- Locations
- 1
- Primary Endpoint
- progression free survival
- Status
- Withdrawn
- Last Updated
- 10 years ago
Overview
Brief Summary
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.
Detailed Description
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated
Investigators
e_dann
Prof Eldad Dann
Rambam Health Care Campus
Eligibility Criteria
Inclusion Criteria
- •aggressive non-Hodgkin lymphoma b cells
- •age 18-70
- •bilirubin less then 2
- •creatinine less then 2
- •Pet/CT performed post 2 cycles
Exclusion Criteria
- •no PET/CT post 2 cycles performed
- •bilirubin \>2
- •creatinine more then 2
- •HIV positivity
Outcomes
Primary Outcomes
progression free survival
Time Frame: 5 years
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Prognostic PET/CT Model in Non Small Cell Lung CancerNon Small Cell Lung CancerNCT03199599Poitiers University Hospital150
Completed
Phase 2
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung CancerLung CancerNCT00227539University of Washington25
Active, not recruiting
Phase 2
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast CancerBreast CancerNCT01937117Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins88
Active, not recruiting
Not Applicable
PET-CT Predicting Lymph Nodes MetastasisNon Small Cell Lung CancerLymph Node MetastasisPositron Emission TomographyNCT05970913Fudan University280
Terminated
Phase 1
18F-FLT PET Imaging in Patients With Advanced MelanomaMelanomaNCT02891616Washington University School of Medicine4